Pfizer Inc (PFE) 29.71 $PFE
Better Buy: Pfizer Inc. vs. Merck
Dan Caplinger, The Motley Fool - Motley Fool - Sat Mar 05, 8:03AM CST
Image source: Merck. The pharmaceutical sector has taken political fire lately, and the presidential election has opened up drugmakers to criticisms about what they charge for their products. Pfizer and Merck have both seen their share...
PFE: 29.71 (-0.18), MRK: 52.08 (-0.02)
Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.37 (-0.06), SNDX: 11.85 (-0.16), PFE: 29.71 (-0.18)
Covered Call Alerts For Whiting Petroleum, Pfizer Inc., Transocean, GOL Linhas and Southwestern Energy Company Released By InvestorsObserver
PR Newswire - Fri Mar 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for WLL, PFE, RIG, GOL and SWN.
WLL: 7.09 (+0.78), RIG: 12.71 (+1.88), PFE: 29.71 (-0.18), GOL: 8.52 (-1.56), SWN: 7.83 (+0.49)
J&J, Pfizer, Merck, UnitedHealth -- Buy Them, Not the Health Care ETF
at The Street - Fri Mar 04, 7:13AM CST
These brand-name stocks are outperforming the exchange-traded fund.
JNJ: 106.50 (-0.15), UNH: 121.80 (-0.02), MRK: 52.08 (-0.02), PFE: 29.71 (-0.18), XLV: 67.41 (-0.16)
Why Opko Health Skyrocketed 17.4% in February
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 03, 7:23PM CST
SOURCE: OPKO HEALTH. What: Ahead of its fourth-quarter earnings release on February 29 and a key FDA approval decision slated for March 29, shares in Opko Health jumped by 17.4% in February. So What: Opko Health is run by iconic healthcare...
TSRO: 43.78 (+0.03), OPK: 9.70 (+0.10), PFE: 29.71 (-0.18)
US stocks climb again as energy companies keep rising
By MARLEY JAY - AP - Thu Mar 03, 3:35PM CST
NEW YORK (AP) — Stocks made modest gains on Thursday as the market once again turned higher late in the day. Energy stocks led the way as investors continued to hope that oil prices have stabilized after almost two years of steep declines.
AGN: 288.67 (-0.95), ABT: 39.18 (+0.36), JNJ: 106.50 (-0.15), KR: 36.84 (-0.96), PFE: 29.71 (-0.18), COST: 150.90 (-0.70)
AstraZeneca's Faslodex Gains FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 12:10PM CST
AstraZeneca (AZN) announced a label expansion for its breast cancer drug, Faslodex, in the U.S.
PFE: 29.71 (-0.18), AZN: 28.87 (+0.13), HZNP: 16.78 (-0.51), ANIK: 45.07 (-0.43)
Watch for Shares of Pfizer (PFE) to Approach Support at $29.55
Comtex SmarTrend(R) - Thu Mar 03, 10:20AM CST
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $29.96 today and have reached the first support level of $29.77. Investors may be interested in a cross of the next downside pivot targets of $29.55 and $29.14.
PFE: 29.71 (-0.18)
Dogs Of The Dow: It's Intel, Not Caterpillar, Expected To Gain 41% By March 2017
Fredrik Arnold - at Seeking Alpha - Thu Mar 03, 8:18AM CST
AXP: 58.29 (+0.20), NKE: 61.26 (-0.21), UNH: 121.80 (-0.02), PFE: 29.71 (-0.18), XOM: 82.29 (-0.11), BA: 121.07 (+1.46), INTC: 30.63 (+0.05), GS: 156.84 (+1.51), JPM: 60.05 (+0.09), IBM: 137.80 (unch), MRK: 52.08 (-0.02), PG: 83.49 (+0.65), CAT: 72.84 (+1.09), CVX: 87.93 (+0.40), MSFT: 52.03 (-0.32), VZ: 51.81 (-0.08), CSCO: 26.80 (-0.07)
Merck KGaA, Pfizer and Verastem team up to assess avelumab/VS-6063 combo in ovarian cancer
Seeking Alpha - at Seeking Alpha - Thu Mar 03, 7:11AM CST
VSTM: 1.37 (-0.06), PFE: 29.71 (-0.18)
FDA clears new indication for AstraZeneca's FASLODEX
Seeking Alpha - at Seeking Alpha - Thu Mar 03, 6:34AM CST
PFE: 29.71 (-0.18), AZN: 28.87 (+0.13)
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Business Wire - Thu Mar 03, 6:15AM CST
Merck, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.37 (-0.06), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02)
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Business Wire - Thu Mar 03, 6:00AM CST
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.37 (-0.06), PFE: 29.71 (-0.18)
Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
DoctoRx - at Seeking Alpha - Wed Mar 02, 2:28PM CST
JNJ: 106.50 (-0.15), PTLA: 29.71 (-1.04), XBI: 51.94 (+0.22), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02), AMGN: 145.98 (+0.14), SNY: 39.81 (+0.19), REGN: 403.82 (+1.88)
How This $1.6 Billion Company May Change a $10 Billion Market
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Wed Mar 02, 10:38AM CST
The decades-long dominance of warfarin as a therapy to prevent blood clots is already coming to an end, thanks to rising use of Johnson & Johnson Xarelto and Bristol-Myers Squibb and Pfizer 's Eliquis. However, warfarin's decline could...
JNJ: 106.50 (-0.15), PTLA: 29.71 (-1.04), PFE: 29.71 (-0.18), BMY: 64.71 (-0.29)
Stocks Struggle With Thin Losses; February Jobs Data Tops Views
at Investor's Business Daily - Wed Mar 02, 9:39AM CST
Stocks opened to thin losses Wednesday, but the Nasdaq flicked in and out of positive territory. The Dow industrials and S&P 500 eased about 0.1% each, with the Nasdaq moving between fractional gains and losses. Things might have been worse in the...
MON: 85.89 (+0.95), NKE: 61.26 (-0.21), ORLY: 265.31 (-2.62), STX: 34.53 (-0.22), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02), WDC: 48.86 (+0.20), AAPL: 103.01 (+1.51), ROST: 57.42 (-0.43)
The Perfect Porftolio: What We Are Buying Right Now (Part 2)
David Crosetti - at Seeking Alpha - Sun Feb 21, 6:40AM CST
RAI: 51.71 (+0.45), KO: 44.11 (+0.15), ABT: 39.18 (+0.36), PFE: 29.71 (-0.18), KMB: 132.54 (+0.91), EMR: 51.26 (+0.47), XOM: 82.29 (-0.11), CNP: 19.49 (+0.71), MO: 62.98 (+0.75), INTC: 30.63 (+0.05), SO: 48.63 (+0.44), T: 37.93 (-0.06), JNJ: 106.50 (-0.15), JPM: 60.05 (+0.09), QCOM: 52.66 (+0.28), MCD: 117.18 (+0.49), ABBV: 56.15 (+0.22), PG: 83.49 (+0.65), MSFT: 52.03 (-0.32), CVX: 87.93 (+0.40), VZ: 51.81 (-0.08), CSCO: 26.80 (-0.07), CL: 68.16 (+0.55)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sun Feb 21, 6:17AM CST
SIRO: 109.97 (-0.13), MON: 85.89 (+0.95), EVHC: 23.25 (-0.30), PRU: 71.47 (-0.40), NKE: 61.26 (-0.21), KSU: 86.65 (+0.23), AMP: 90.46 (+0.92), LM: 32.42 (+0.57), RRC: 32.32 (+1.59), AET: 108.06 (-1.58), GOOG: 710.89 (-1.53), GPOR: 25.60 (+0.33), HOT: 70.55 (+0.48), HLT: 21.89 (+0.30), LYB: 82.00 (+2.10), COG: 21.47 (-0.70), WCG: 93.24 (-0.36), MA: 90.05 (+0.31), MNK: 62.15 (-1.44), WUBA: 55.70 (+1.45), WLL: 7.09 (+0.78), VRTX: 88.36 (-1.09), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), SEE: 45.68 (-0.84), AKRX: 25.08 (-0.80), PFE: 29.71 (-0.18), HAL: 34.88 (+0.71), LNG: 38.04 (+0.99), ETE: 8.33 (+0.43), TXT: 33.00 (-0.64), ALL: 65.38 (+0.07), PCLN: 1,297.71 (-5.33), QUNR: 36.95 (+0.73), WBA: 79.45 (-0.47), PXD: 128.80 (+0.53), MCD: 117.18 (+0.49), TEVA: 55.62 (+0.02), DOV: 63.20 (+0.75), AIG: 52.30 (+0.03), XRAY: 60.16 (-0.46), FDC: 13.59 (+0.80), CCI: 87.25 (-0.64), BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), CPN: 14.14 (+0.26), C: 42.83 (unch), ILMN: 156.14 (-1.31), CB: 117.18 (-0.66), MMC: 58.01 (+0.26), HUM: 183.25 (+0.03), AGN: 288.67 (-0.95), ANTM: 132.35 (-0.62), ECA: 5.47 (+0.54), PRQR: 4.54 (+0.14), EBAY: 24.41 (+0.47), SHPG: 160.39 (+0.20), CMG: 529.00 (+4.71), GOOGL: 730.22 (-1.37), CTRP: 40.02 (+0.78), SWN: 7.83 (+0.49), BK: 38.09 (+0.40), APD: 134.79 (-0.09), BHI: 46.20 (-0.35), APC: 45.26 (+2.28), AMZN: 575.14 (-2.35), ENDP: 42.44 (-0.73), MAR: 68.98 (+0.30), NFLX: 101.58 (+3.65), DVA: 70.51 (+0.43), KITE: 54.44 (+2.70), MHK: 186.82 (-0.07), TDG: 222.68 (+3.05), LH: 112.17 (+0.25), CP: 125.26 (+3.28), AFL: 61.03 (+0.05), AVGO: 146.06 (+8.73), BABA: 72.22 (+1.20)
Pfizer's Stock Price Is Scheduled To Pop
Nicholas Mushaike - at Seeking Alpha - Sun Feb 21, 3:55AM CST
PFE: 29.71 (-0.18)
Retirement Income Doesn’t Have to Be a Dream -- 3 Dividend Stocks That Could Make It a Reality
Brian Feroldi, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 7:20PM CST
Image by TBIT via pixabay. With interest rates near record lows, many retirees have been forced into the stock market as a way to generate income. While that can be a savvy move, it's incredibly important for those investors to only put their money...
SPY: 200.43 (+0.65), HCP: 31.50 (+0.12), PFE: 29.71 (-0.18), VZ: 51.81 (-0.08)
Better Buy: Pfizer Inc. vs. Merck
Dan Caplinger, The Motley Fool - Motley Fool - Sat Mar 05, 8:03AM CST
Image source: Merck. The pharmaceutical sector has taken political fire lately, and the presidential election has opened up drugmakers to criticisms about what they charge for their products. Pfizer and Merck have both seen their share...
PFE: 29.71 (-0.18), MRK: 52.08 (-0.02)
Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.37 (-0.06), SNDX: 11.85 (-0.16), PFE: 29.71 (-0.18)
Covered Call Alerts For Whiting Petroleum, Pfizer Inc., Transocean, GOL Linhas and Southwestern Energy Company Released By InvestorsObserver
PR Newswire - Fri Mar 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for WLL, PFE, RIG, GOL and SWN.
WLL: 7.09 (+0.78), RIG: 12.71 (+1.88), PFE: 29.71 (-0.18), GOL: 8.52 (-1.56), SWN: 7.83 (+0.49)
J&J, Pfizer, Merck, UnitedHealth -- Buy Them, Not the Health Care ETF
at The Street - Fri Mar 04, 7:13AM CST
These brand-name stocks are outperforming the exchange-traded fund.
JNJ: 106.50 (-0.15), UNH: 121.80 (-0.02), MRK: 52.08 (-0.02), PFE: 29.71 (-0.18), XLV: 67.41 (-0.16)
Why Opko Health Skyrocketed 17.4% in February
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 03, 7:23PM CST
SOURCE: OPKO HEALTH. What: Ahead of its fourth-quarter earnings release on February 29 and a key FDA approval decision slated for March 29, shares in Opko Health jumped by 17.4% in February. So What: Opko Health is run by iconic healthcare...
TSRO: 43.78 (+0.03), OPK: 9.70 (+0.10), PFE: 29.71 (-0.18)
US stocks climb again as energy companies keep rising
By MARLEY JAY - AP - Thu Mar 03, 3:35PM CST
NEW YORK (AP) — Stocks made modest gains on Thursday as the market once again turned higher late in the day. Energy stocks led the way as investors continued to hope that oil prices have stabilized after almost two years of steep declines.
AGN: 288.67 (-0.95), ABT: 39.18 (+0.36), JNJ: 106.50 (-0.15), KR: 36.84 (-0.96), PFE: 29.71 (-0.18), COST: 150.90 (-0.70)
AstraZeneca's Faslodex Gains FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 12:10PM CST
AstraZeneca (AZN) announced a label expansion for its breast cancer drug, Faslodex, in the U.S.
PFE: 29.71 (-0.18), AZN: 28.87 (+0.13), HZNP: 16.78 (-0.51), ANIK: 45.07 (-0.43)
Watch for Shares of Pfizer (PFE) to Approach Support at $29.55
Comtex SmarTrend(R) - Thu Mar 03, 10:20AM CST
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $29.96 today and have reached the first support level of $29.77. Investors may be interested in a cross of the next downside pivot targets of $29.55 and $29.14. PFE: 29.71 (-0.18)
Dogs Of The Dow: It's Intel, Not Caterpillar, Expected To Gain 41% By March 2017
Fredrik Arnold - at Seeking Alpha - Thu Mar 03, 8:18AM CST
AXP: 58.29 (+0.20), NKE: 61.26 (-0.21), UNH: 121.80 (-0.02), PFE: 29.71 (-0.18), XOM: 82.29 (-0.11), BA: 121.07 (+1.46), INTC: 30.63 (+0.05), GS: 156.84 (+1.51), JPM: 60.05 (+0.09), IBM: 137.80 (unch), MRK: 52.08 (-0.02), PG: 83.49 (+0.65), CAT: 72.84 (+1.09), CVX: 87.93 (+0.40), MSFT: 52.03 (-0.32), VZ: 51.81 (-0.08), CSCO: 26.80 (-0.07)
Merck KGaA, Pfizer and Verastem team up to assess avelumab/VS-6063 combo in ovarian cancer
Seeking Alpha - at Seeking Alpha - Thu Mar 03, 7:11AM CST
VSTM: 1.37 (-0.06), PFE: 29.71 (-0.18)
FDA clears new indication for AstraZeneca's FASLODEX
Seeking Alpha - at Seeking Alpha - Thu Mar 03, 6:34AM CST
PFE: 29.71 (-0.18), AZN: 28.87 (+0.13)
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Business Wire - Thu Mar 03, 6:15AM CST
Merck, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.37 (-0.06), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02)
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Business Wire - Thu Mar 03, 6:00AM CST
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.37 (-0.06), PFE: 29.71 (-0.18)
Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
DoctoRx - at Seeking Alpha - Wed Mar 02, 2:28PM CST
JNJ: 106.50 (-0.15), PTLA: 29.71 (-1.04), XBI: 51.94 (+0.22), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02), AMGN: 145.98 (+0.14), SNY: 39.81 (+0.19), REGN: 403.82 (+1.88)
How This $1.6 Billion Company May Change a $10 Billion Market
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Wed Mar 02, 10:38AM CST
The decades-long dominance of warfarin as a therapy to prevent blood clots is already coming to an end, thanks to rising use of Johnson & Johnson Xarelto and Bristol-Myers Squibb and Pfizer 's Eliquis. However, warfarin's decline could...
JNJ: 106.50 (-0.15), PTLA: 29.71 (-1.04), PFE: 29.71 (-0.18), BMY: 64.71 (-0.29)
Stocks Struggle With Thin Losses; February Jobs Data Tops Views
at Investor's Business Daily - Wed Mar 02, 9:39AM CST
Stocks opened to thin losses Wednesday, but the Nasdaq flicked in and out of positive territory. The Dow industrials and S&P 500 eased about 0.1% each, with the Nasdaq moving between fractional gains and losses. Things might have been worse in the...
MON: 85.89 (+0.95), NKE: 61.26 (-0.21), ORLY: 265.31 (-2.62), STX: 34.53 (-0.22), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02), WDC: 48.86 (+0.20), AAPL: 103.01 (+1.51), ROST: 57.42 (-0.43)
The Perfect Porftolio: What We Are Buying Right Now (Part 2)
David Crosetti - at Seeking Alpha - Sun Feb 21, 6:40AM CST
RAI: 51.71 (+0.45), KO: 44.11 (+0.15), ABT: 39.18 (+0.36), PFE: 29.71 (-0.18), KMB: 132.54 (+0.91), EMR: 51.26 (+0.47), XOM: 82.29 (-0.11), CNP: 19.49 (+0.71), MO: 62.98 (+0.75), INTC: 30.63 (+0.05), SO: 48.63 (+0.44), T: 37.93 (-0.06), JNJ: 106.50 (-0.15), JPM: 60.05 (+0.09), QCOM: 52.66 (+0.28), MCD: 117.18 (+0.49), ABBV: 56.15 (+0.22), PG: 83.49 (+0.65), MSFT: 52.03 (-0.32), CVX: 87.93 (+0.40), VZ: 51.81 (-0.08), CSCO: 26.80 (-0.07), CL: 68.16 (+0.55)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sun Feb 21, 6:17AM CST
SIRO: 109.97 (-0.13), MON: 85.89 (+0.95), EVHC: 23.25 (-0.30), PRU: 71.47 (-0.40), NKE: 61.26 (-0.21), KSU: 86.65 (+0.23), AMP: 90.46 (+0.92), LM: 32.42 (+0.57), RRC: 32.32 (+1.59), AET: 108.06 (-1.58), GOOG: 710.89 (-1.53), GPOR: 25.60 (+0.33), HOT: 70.55 (+0.48), HLT: 21.89 (+0.30), LYB: 82.00 (+2.10), COG: 21.47 (-0.70), WCG: 93.24 (-0.36), MA: 90.05 (+0.31), MNK: 62.15 (-1.44), WUBA: 55.70 (+1.45), WLL: 7.09 (+0.78), VRTX: 88.36 (-1.09), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), SEE: 45.68 (-0.84), AKRX: 25.08 (-0.80), PFE: 29.71 (-0.18), HAL: 34.88 (+0.71), LNG: 38.04 (+0.99), ETE: 8.33 (+0.43), TXT: 33.00 (-0.64), ALL: 65.38 (+0.07), PCLN: 1,297.71 (-5.33), QUNR: 36.95 (+0.73), WBA: 79.45 (-0.47), PXD: 128.80 (+0.53), MCD: 117.18 (+0.49), TEVA: 55.62 (+0.02), DOV: 63.20 (+0.75), AIG: 52.30 (+0.03), XRAY: 60.16 (-0.46), FDC: 13.59 (+0.80), CCI: 87.25 (-0.64), BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), CPN: 14.14 (+0.26), C: 42.83 (unch), ILMN: 156.14 (-1.31), CB: 117.18 (-0.66), MMC: 58.01 (+0.26), HUM: 183.25 (+0.03), AGN: 288.67 (-0.95), ANTM: 132.35 (-0.62), ECA: 5.47 (+0.54), PRQR: 4.54 (+0.14), EBAY: 24.41 (+0.47), SHPG: 160.39 (+0.20), CMG: 529.00 (+4.71), GOOGL: 730.22 (-1.37), CTRP: 40.02 (+0.78), SWN: 7.83 (+0.49), BK: 38.09 (+0.40), APD: 134.79 (-0.09), BHI: 46.20 (-0.35), APC: 45.26 (+2.28), AMZN: 575.14 (-2.35), ENDP: 42.44 (-0.73), MAR: 68.98 (+0.30), NFLX: 101.58 (+3.65), DVA: 70.51 (+0.43), KITE: 54.44 (+2.70), MHK: 186.82 (-0.07), TDG: 222.68 (+3.05), LH: 112.17 (+0.25), CP: 125.26 (+3.28), AFL: 61.03 (+0.05), AVGO: 146.06 (+8.73), BABA: 72.22 (+1.20)
Pfizer's Stock Price Is Scheduled To Pop
Nicholas Mushaike - at Seeking Alpha - Sun Feb 21, 3:55AM CST
PFE: 29.71 (-0.18)
Retirement Income Doesn’t Have to Be a Dream -- 3 Dividend Stocks That Could Make It a Reality
Brian Feroldi, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 7:20PM CST
Image by TBIT via pixabay. With interest rates near record lows, many retirees have been forced into the stock market as a way to generate income. While that can be a savvy move, it's incredibly important for those investors to only put their money...
SPY: 200.43 (+0.65), HCP: 31.50 (+0.12), PFE: 29.71 (-0.18), VZ: 51.81 (-0.08)
